N Fernández-Hidalgo1, A Ribera2, M N Larrosa3, E Viedma4, J Origüen5, A de Alarcón6, M C Fariñas7, C Sáez8, C Peña9, E Múñez10, M V García López11, J Gavaldà12, D Pérez-Montarelo4, F Chaves4, B Almirante12. 1. Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Universitat Autonoma de Barcelona, Barcelona, Spain; Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: nufernan@gmail.com. 2. Cardiovascular Epidemiology Unit, Cardiology Department, Vall d'Hebron University Hospital, CIBERESP, Barcelona, Spain. 3. Universitat Autonoma de Barcelona, Barcelona, Spain; Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015), Instituto de Salud Carlos III, Madrid, Spain; Servei de Microbiologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. 4. Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015), Instituto de Salud Carlos III, Madrid, Spain; Servicio de Microbiologia, Hospital Universitario 12 de Octubre, Madrid, Spain. 5. Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015), Instituto de Salud Carlos III, Madrid, Spain; Unit of Infectious Diseases, Hospital Universitario 12 de Octubre, Instituto de Investigacion Hospital 12 de Octubre (i+12), School of Medicine, Universidad Complutense, Madrid, Spain. 6. Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015), Instituto de Salud Carlos III, Madrid, Spain; Clinical Unit of Infectious Diseases, Microbiology, and Preventive Medicine, Infectious Diseases Research Group, Institute of Biomedicine of Seville, University of Seville/CSIC/University Hospital Virgen del Rocio, Seville, Spain. 7. Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015), Instituto de Salud Carlos III, Madrid, Spain; Infectious Diseases Unit, Hospital Universitario Marques de Valdecilla, University of Cantabria, Santander, Spain. 8. Unidad de Infecciosas, Hospital de la Princesa, Instituto de Investigacion, Madrid, Spain. 9. Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015), Instituto de Salud Carlos III, Madrid, Spain; Servei de Malalties Infeccioses, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain; Servei de Medicina Interna, Hospital Mare de Deu dels Lliris, Alcoi, Spain. 10. Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario Puerta de Hierro, Majadahonda, Spain. 11. Servicio de Microbiologia, Hospital Universitario Virgen de la Victoria, Instituto de Investigacion Biomedica, Malaga, Spain. 12. Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Universitat Autonoma de Barcelona, Barcelona, Spain; Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015), Instituto de Salud Carlos III, Madrid, Spain.
Abstract
OBJECTIVE: We aimed to evaluate the impact of Staphylococcus aureus phenotype (vancomycin MIC) and genotype (agr group, clonal complex CC) on the prognosis and clinical characteristics of infective endocarditis (IE). METHODS: We performed a multicentre, longitudinal, prospective, observational study (June 2013 to March 2016) in 15 Spanish hospitals. Two hundred and thirteen consecutive adults (≥18 years) with a definite diagnosis of S. aureus IE were included. Primary outcome was death during hospital stay. Main secondary end points were persistent bacteraemia, sepsis/septic shock, peripheral embolism and osteoarticular involvement. RESULTS: Overall in-hospital mortality was 37% (n = 72). Independent risk factors for death were age-adjusted Charlson co-morbidity index (OR 1.20; 95% CI 1.08-1.34), congestive heart failure (OR 3.60; 95% CI 1.72-7.50), symptomatic central nervous system complication (OR 3.17; 95% CI 1.41-7.11) and severe sepsis/septic shock (OR 4.41; 95% CI 2.18-8.96). In the subgroup of methicillin-susceptible S. aureus IE (n = 173), independent risk factors for death were the age-adjusted Charlson co-morbidity index (OR 1.17; 95% CI 1.03-1.31), congestive heart failure (OR 3.39; 95% CI 1.51-7.64), new conduction abnormality (OR 4.42; 95% CI 1.27-15.34), severe sepsis/septic shock (OR 5.76; 95% CI 2.57-12.89) and agr group III (OR 0.27; 0.10-0.75). Vancomycin MIC ≥1.5 mg/L was not independently associated with death during hospital nor was it related to secondary end points. No other genotype variables were independently associated with in-hospital death. CONCLUSIONS: This is the first prospective study to assess the impact of S. aureus phenotype and genotype. Phenotype and genotype provided no additional predictive value beyond conventional clinical characteristics. No evidence was found to justify therapeutic decisions based on vancomycin MIC for either methicillin-resistant or methicillin-susceptible S. aureus.
OBJECTIVE: We aimed to evaluate the impact of Staphylococcus aureus phenotype (vancomycin MIC) and genotype (agr group, clonal complex CC) on the prognosis and clinical characteristics of infective endocarditis (IE). METHODS: We performed a multicentre, longitudinal, prospective, observational study (June 2013 to March 2016) in 15 Spanish hospitals. Two hundred and thirteen consecutive adults (≥18 years) with a definite diagnosis of S. aureus IE were included. Primary outcome was death during hospital stay. Main secondary end points were persistent bacteraemia, sepsis/septic shock, peripheral embolism and osteoarticular involvement. RESULTS: Overall in-hospital mortality was 37% (n = 72). Independent risk factors for death were age-adjusted Charlson co-morbidity index (OR 1.20; 95% CI 1.08-1.34), congestive heart failure (OR 3.60; 95% CI 1.72-7.50), symptomatic central nervous system complication (OR 3.17; 95% CI 1.41-7.11) and severe sepsis/septic shock (OR 4.41; 95% CI 2.18-8.96). In the subgroup of methicillin-susceptible S. aureus IE (n = 173), independent risk factors for death were the age-adjusted Charlson co-morbidity index (OR 1.17; 95% CI 1.03-1.31), congestive heart failure (OR 3.39; 95% CI 1.51-7.64), new conduction abnormality (OR 4.42; 95% CI 1.27-15.34), severe sepsis/septic shock (OR 5.76; 95% CI 2.57-12.89) and agr group III (OR 0.27; 0.10-0.75). Vancomycin MIC ≥1.5 mg/L was not independently associated with death during hospital nor was it related to secondary end points. No other genotype variables were independently associated with in-hospital death. CONCLUSIONS: This is the first prospective study to assess the impact of S. aureus phenotype and genotype. Phenotype and genotype provided no additional predictive value beyond conventional clinical characteristics. No evidence was found to justify therapeutic decisions based on vancomycin MIC for either methicillin-resistant or methicillin-susceptible S. aureus.
Authors: Eloise D Austin; Sean S Sullivan; Nenad Macesic; Monica Mehta; Benjamin A Miko; Saman Nematollahi; Qiuhu Shi; Franklin D Lowy; Anne-Catrin Uhlemann Journal: Clin Infect Dis Date: 2020-04-10 Impact factor: 9.079
Authors: Maria Souli; Felicia Ruffin; Seong-Ho Choi; Lawrence P Park; Shengli Gao; Nicholas Christopoulos Lent; Batu K Sharma-Kuinkel; Joshua T Thaden; Stacey A Maskarinec; Lisa Wanda; Jonathan Hill-Rorie; Bobby Warren; Brenda Hansen; Vance G Fowler Journal: Clin Infect Dis Date: 2019-11-13 Impact factor: 9.079
Authors: Juan M Pericàs; Carlos Cervera; Cristina Garcia-de-la-Mària; Batu K Sharma-Kuinkel; Rachelle Gonzales; Asunción Moreno; Manel Almela; Carlos Falces; Eduard Quintana; David Fuster; Francesc Marco; Arnold S Bayer; Vance G Fowler; José M Miró Journal: Antimicrob Agents Chemother Date: 2020-02-21 Impact factor: 5.191
Authors: Carmen Hidalgo-Tenorio; Juan Gálvez; Francisco Javier Martínez-Marcos; Antonio Plata-Ciezar; Javier De La Torre-Lima; Luis Eduardo López-Cortés; Mariam Noureddine; José M Reguera; David Vinuesa; Maria Victoria García; Guillermo Ojeda; Rafael Luque; José Manuel Lomas; Jose Antonio Lepe; Arístides de Alarcón Journal: BMC Infect Dis Date: 2020-02-21 Impact factor: 3.090